Arcutis shares traded higher on Monday after Health Canada approved its Zoryve cream for the treatment of mild to moderate ...
Once-daily roflumilast cream 0.05% is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 years, according ...
Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease ...
A new survey commissioned by Leo Pharma confirms there’s plenty of room in the market for its chronic hand eczema treatment ...
Approximately 35 million individuals in the U.S. suffer from atopic dermatitis and psoriasis, highlighting a substantial market opportunity for ZORYVE products. Recognition of ZORYVE cream for ...
Atopic dermatitis disease activity remained mild after patients treated with Vtama cream 1% achieved nearly 80 consecutive ...
Lawrence F. Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the effectiveness of ruxolitinib cream as a nonsteroidal topical treatment for atopic ...
Data demonstrated favorable safety and local tolerability of ZORYVE® (roflumilast) cream 0.15% in adults and children with atopic dermatitis (AD) ...
Once-daily roflumilast cream 0.05 percent is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 ye ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results